✦ LIBER ✦
467 Updated efficacy and safety results for a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P) and bevacizumab (B) in stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC): The FALCON trial
✍ Scribed by E.B. Garon; J. Neidhart; J.D. Neidhart; F. Kabbinavar; N. Gabrail; M. Ribeiro de Oliveira; S.P. Lu; J. Balkissoon
- Book ID
- 119603150
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 45 KB
- Volume
- 8
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.